TEHRAN, Sep. 08 (MNA) – Deputy health minister has reported on the entry of home-made Hepatitis C drug to the country’s pharmaceutical market next week noting that it has been produced by Iranian knowledge-based companies.
“The Sofosbuvir drug is used to treat hepatitis C cases; previously it was imported from other countries and priced at $100 per tablet but the indigenous version will be available at the price of 10 dollars per tablet,” said Reza Malekzadeh at a press conference on knowledge-based companies reminding that, “in terms of quality, this drug fully complies with foreign ones and there is no difference in terms of efficiency or treatment of the disease.”
He also reported the production of two other combination drugs to treat hepatitis C in the country adding that they are currently at laboratory stage and will soon be released. “There are now drugs that can treat hepatitis C and there exists the possibility of eradication of the hepatitis C virus in the country in near future; hepatitis C has a three-month course of treatment and patients should take one tablet per day for full treatment,” added Malekzadeh.
Read more...
Showing posts with label generic Sovaldi. Show all posts
Showing posts with label generic Sovaldi. Show all posts
Tuesday, September 8, 2015
Friday, April 24, 2015
India: Mylan Pharmaceuticals launches generic hepatitis C drug MyHep in India
NEW DELHI: Drugmaker Mylan Pharmaceuticals today launched generic Sofosbuvir tablets, indicated for the treatment of chronic hepatitis C, in the country.
US-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, it said in a statement.
"The launch of Mylan's MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option."
US-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, it said in a statement.
"The launch of Mylan's MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option."
Friday, March 27, 2015
India: Strides Arcolab Launches Generic Version of Hepatitis C Drug
New Delhi: Strides Arcolab on announced launch of the generic version of Hepatitis C drug 'Sofosbuvir' under the brand name 'Virso'.
The product will be available to Indian patients shortly, the Bangalore-based company said in a statement.
"In September 2014, Strides entered into a licensing agreement with Gilead Sciences Inc to bring Hepatitis C cure to 91 developing countries," Strides Arcolab said in a statement.
Read more...
The product will be available to Indian patients shortly, the Bangalore-based company said in a statement.
"In September 2014, Strides entered into a licensing agreement with Gilead Sciences Inc to bring Hepatitis C cure to 91 developing countries," Strides Arcolab said in a statement.
Read more...
Wednesday, March 11, 2015
Incepta Pharmaceuticals launches generic version of Sovaldi
Incepta Pharmaceuticals has brought a generic version of the drug Sovaldi, of the Gilead Sciences, which is being used in treatment of hepatitis C, is a very popular drug. The generic version of the drug will be sold at a price of $10.
The generic drug of Sovaldi is named as Hopetavir and the cost of the drug for a period of 12 weeks will be $900. Cost of Gilead Sciences Inc.'s Sovaldi is very high. "Gilead is aware of unauthorized generic versions of sofosbuvir being offered in the marketplace .We're focused on enabling our eleven Indian generic partners to launch their authorized generic versions as soon as possible", the company said in an e-mail.
So far, it was the most successful drug for treating hepatitis C. And the cost of this drug for a period of twelve weeks was $86,000.
Read more...
The generic drug of Sovaldi is named as Hopetavir and the cost of the drug for a period of 12 weeks will be $900. Cost of Gilead Sciences Inc.'s Sovaldi is very high. "Gilead is aware of unauthorized generic versions of sofosbuvir being offered in the marketplace .We're focused on enabling our eleven Indian generic partners to launch their authorized generic versions as soon as possible", the company said in an e-mail.
So far, it was the most successful drug for treating hepatitis C. And the cost of this drug for a period of twelve weeks was $86,000.
Read more...
Tuesday, March 10, 2015
India: Natco to launch Hepatitis C drug in India soon
Natco Pharma plans to launch the generic version of Sovaldi, the blockbuster drug used to treat chronic Hepatitis C in India soon. Sovaldi is made by U.S. pharma major Gilead Sciences, and Natco recently entered into a non-exclusive licensing agreement with Gilead to make and sell generic versions of Sovaldi in 91 developing countries.
The company, on Monday, launched the generic version of Sovaldi in Nepal under the brand Hepcinat. The product is priced at Rs.19,900 (US $316.68) per bottle of 28 tablets in Nepal, and covers the treatment duration of three months for a patient.
“We will be launching the drug in the next few weeks in India, and are awaiting approval from the Drugs Controller General of India (DCGI),” M. Adinarayana, Vice-President, Legal & Corporate Affairs, Natco Pharma, told this correspondent.
Monday, March 9, 2015
Nepal: Natco Pharma up 4%, launches hepatitis C drug in Nepal
Shares of Natco Pharma gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal. "Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI)," said the company in its filing to the exchange.
Read more at: http://www.moneycontrol.com/news/buzzing-stocks/natco-pharma4-launches-hepatitis-c-drugnepal_1323547.html?utm_source=ref_article
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal. "Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI)," said the company in its filing to the exchange.
Read more at: http://www.moneycontrol.com/news/buzzing-stocks/natco-pharma4-launches-hepatitis-c-drugnepal_1323547.html?utm_source=ref_article
Bangladesh: $10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh
(Bloomberg) -- A $10 version of Sovaldi, the Gilead Sciences Inc. hepatitis C treatment that sells for $1,000 a pill in the U.S., is now available in Bangladesh and could make its way to other parts of the world where the U.S. company doesn’t have patents.
Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.
The generic drugmaker has beaten to the market a number of larger Indian competitors that were licensed by Gilead to produce low-cost versions of Sovaldi for 91 countries that are mostly poor. Nations not covered by Gilead’s license, including Thailand, Malaysia and Morocco, and countries where Sovaldi isn’t patented could benefit from the new source of cheap copies.
Read more...
Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.
The generic drugmaker has beaten to the market a number of larger Indian competitors that were licensed by Gilead to produce low-cost versions of Sovaldi for 91 countries that are mostly poor. Nations not covered by Gilead’s license, including Thailand, Malaysia and Morocco, and countries where Sovaldi isn’t patented could benefit from the new source of cheap copies.
Read more...
Monday, March 2, 2015
India: Natco Pharma ties up with Gilead on hepatitis C drugs
(Reuters) - Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations.
Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.
Read more...
Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.
Read more...
Saturday, January 31, 2015
Delhi HC sets aside order on Gilead’s Sovaldi patent
New Delhi: In a setback to generic drug makers, the Delhi high court on Friday set aside an order of the Deputy Controller of Patents and Designs rejecting a patent to US drug maker Gilead Pharmasset Llc for the hepatitis C drug Sovaldi.
The medicine costs $1,000 a pill and cures hepatitis C in 90% of cases when given for a 12-week course. India’s patent office had questioned the therapeutic efficacy under which the patent was claimed by Gilead and rejected its application using the controversial Section 3(d) of the Patents Act, which prevents evergreening of patents and provides that no new form of an existing substance shall be patented unless the new form is much more effective than the old one.
The Indian patent office, while rejecting the patent application, had maintained that minor changes in the molecule did not improve its efficacy. With the patent set aside, domestic generic drug manufacturers could make the same drug for as low as $1 a pill. “It was expected that the appeal would succeed because the process of reasoning in the controller’s order was really shoddy, without commenting on the merits of the conclusion,” said Shamnad Basheer, former professor at National University of Juridical Sciences, Kolkata, and founder of intellectual property blog SpicyIP.
Read more at: http://www.livemint.com/Politics/1l6EyoCRGd45A6oT0qpsBO/Delhi-high-court-sets-aside-order-on-Gileads-Sovaldi-patent.html?utm_source=copy
The medicine costs $1,000 a pill and cures hepatitis C in 90% of cases when given for a 12-week course. India’s patent office had questioned the therapeutic efficacy under which the patent was claimed by Gilead and rejected its application using the controversial Section 3(d) of the Patents Act, which prevents evergreening of patents and provides that no new form of an existing substance shall be patented unless the new form is much more effective than the old one.
The Indian patent office, while rejecting the patent application, had maintained that minor changes in the molecule did not improve its efficacy. With the patent set aside, domestic generic drug manufacturers could make the same drug for as low as $1 a pill. “It was expected that the appeal would succeed because the process of reasoning in the controller’s order was really shoddy, without commenting on the merits of the conclusion,” said Shamnad Basheer, former professor at National University of Juridical Sciences, Kolkata, and founder of intellectual property blog SpicyIP.
Read more at: http://www.livemint.com/Politics/1l6EyoCRGd45A6oT0qpsBO/Delhi-high-court-sets-aside-order-on-Gileads-Sovaldi-patent.html?utm_source=copy
Subscribe to:
Posts (Atom)